A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)

* Participants who had a body mass index 18 to \< 35 kg/m\^2. * Females were either postmenopausal for at least 2 years, surgically sterile, or willing to use at least 2 effective forms of birth control. * Males must have been surgically sterile or agreed to use at least 2 effective forms of birth control throughout the course of the study. * Participants were in a condition of general good health, other than the HCV infection. * Participants had a chronic HCV genotype 1, 2, or 3 infection for at least 6 months, a plasma HCV RNA \> 50,000 IU/mL, and FibroTest score \<= 0.72 and aspartate aminotransferase (AST) to platelet ratio index \<= 2, Fibroscan® result of \< 9.6 kilopascal (kPa), or absence of cirrhosis based on a liver biopsy.

* Positive drug screen * Previous use of anti-HCV agents * History of cardiac disease * History of uncontrolled diabetes or diabetes requiring insulin * Abnormal laboratory results * Females who were pregnant or planned to become pregnant within 6 months after their last dose of study drug/RBV or were breastfeeding; males whose partners were pregnant or would become pregnant within 6 months after their last dose of study drug/RBV * Positive test result for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus (HIV) antibody (Ab). Negative HIV status was to be confirmed at screening.